Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sweet GRAS for “Bitter blocker”

This article was originally published in The Tan Sheet

Executive Summary

FDA affirms adenosine monophosphate (AMP) - a natural compound that can be used to block the bitter taste of oral pharmaceuticals - as generally recognized as safe, Linguagen announces Sept. 15. AMP can "improve the taste" of products "without adding excess salt or sugar" and can be used in foods and beverages, Linguagen notes. The Cranbury, N.J.-based firm received a two-year, $746,000 NIH grant in 2002 to conduct research on AMP's ability to block the bitter taste signal pathway caused by pharmaceutical agents (1"The Tan Sheet" Oct. 7, 2002, p. 12)...

You may also be interested in...



OTC Drug Bitter Taste-Blocking Compound Receives $746,000 NIH Grant

NIH-funded research evaluating the efficacy of a bitter taste-inhibiting compound could result in the development of "more palatable" oral OTC drugs and subsequent improvements in patient compliance, according to grantee Linguagen Corp

UCB And Microsoft Expand AI Tie-Up Beyond COVID-19

Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.

UK: Commercial Framework Sheds Light On Working With NHS And NICE

The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.

Topics

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel